K. Maharry

发表

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

Ulrich Mansmann, Guido Marcucci, Manuela Hummel, 2008, Blood.

A computerized reminder system to increase the use of preventive care for hospitalized patients.

C. McDonald, J. Overhage, P. Dexter, 2001, The New England journal of medicine.

MicroRNA expression in cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2008, The New England journal of medicine.

Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial.

Paul R Dexter, Clement J McDonald, C. McDonald, 2004, JAMA.

MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene

C. Croce, L. Cascione, V. Balatti, 2018, Head and Neck Pathology.

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Guido Marcucci, Christian Buske, Michael Unterhalt, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.

C. Bloomfield, R. Vij, R. Larson, 2010, Blood.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

S. Jaeger, J. Schellens, H. Lenz, 2017, Cancer discovery.

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Haematologica.

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

Supplemental fructose attenuates postprandial glycemia in Zucker fatty fa/fa rats.

K. Maharry, J. Firkins, C. Hadley, 2002, The Journal of nutrition.

Nutrient Metabolism Supplemental Fructose Attenuates Postprandial Glycemia in Zucker Fatty fa/fa Rats

K. Maharry, J. Firkins, C. Hadley, 2002 .

Effects of a beverage containing an enzymatically induced-viscosity dietary fiber, with or without fructose, on the postprandial glycemic response to a high glycemic index food in humans

T. Wolever, C. Bolognesi, K. Maharry, 2003, European Journal of Clinical Nutrition.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

C. Berking, P. Ascierto, J. Sosman, 2017 .

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2014, Leukemia.

Reply to K. Orendi et al.

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

C. Bloomfield, R. Larson, K. Mrózek, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

J. Desai, J. Schellens, J. Tabernero, 2018 .

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2014, The Journal of clinical investigation.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.

M. Caligiuri, C. Bloomfield, C. Plass, 2005, Blood.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2010, Cancer cell.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

M. Caligiuri, C. Bloomfield, R. Vij, 2013, Cancer.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

C. Croce, A. Rosenberg, S. Volinia, 2014, Journal of the National Cancer Institute.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Christian Langer, Guido Marcucci, M. Caligiuri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Guido Marcucci, Stefano Volinia, Jessica Kohlschmidt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

C. Bloomfield, M. Grever, J. Byrd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics

A. Thorburn, G. Marcucci, K. Choi, 2015, Cell Research.

Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.

Guido Marcucci, Christoph Plass, Thomas D. Schmittgen, 2008, Cancer research.

Expression in Acute Myeloid Leukemia α Epigenetic Modification of CCAAT / Enhancer Binding Protein

Thomas D. Schmittgen, C. Bloomfield, C. Plass, 2008 .

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.

M. Caligiuri, C. Bloomfield, C. Plass, 2008, Blood.

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Sp1/NF κ B/HDAC/ miR-29b Regulatory Network in KIT-driven Myeloid Leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2010 .

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

J. Desai, E. Van Cutsem, J. Tabernero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Ulrich Mansmann, Xinan Yang, Guido Marcucci, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007 .

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Leukemia.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.

C. Bloomfield, K. Grzeschik, T. Möröy, 2007, Blood.

Molecular variations in the calcium-sensing receptor in relation to sodium balance and presence of hypertension in blacks and whites.

W. Ambrosius, K. Maharry, M. Wagner, 2000, American journal of hypertension.

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2020, Journal of Clinical Oncology.

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Tabernero, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

C. Bloomfield, M. Radmacher, K. Döhner, 2012, Proceedings of the National Academy of Sciences.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Klaus H. Metzeler, Guido Marcucci, Stefano Volinia, 2013, Leukemia.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

M. Caligiuri, M. Radmacher, K. Metzeler, 2014, Leukemia.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

C. Bloomfield, M. Radmacher, P. Paschka, 2009 .

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

C. Bloomfield, P. Paschka, R. Larson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of Clinical Oncology.

Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia

M. Caligiuri, C. Bloomfield, C. Croce, 2015, Leukemia.

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2011 .

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Leukemia.

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2008, International journal of oncology.

miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53

M. Caligiuri, C. Bloomfield, M. Radmacher, 2014 .

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

E. Van Cutsem, J. Tabernero, R. Yaeger, 2021, ESMO open.

SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

J. Tabernero, R. Yaeger, S. Kopetz, 2020 .

517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

J. Desai, J. Schellens, A. Grothey, 2017 .

myeloid leukemia in acute microRNA-181a up-regulates expression of the antileukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP

C. Bloomfield, J. Byrd, L. J. Lee, 2013 .

Ramasamy myeloid leukemia in acute microRNA-181 a upregulates expression of the antileukemic-p 30 protein α Lenalidomide-mediated enhanced translation of C / EBP

Wu, Krzysztof, Santhanam, 2012 .

G3139, a BCL-2 antisense oligo-nucleotide, in AML.

M. Caligiuri, M. Grever, J. Byrd, 2004, Annals of hematology.

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010 .

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Schellens, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

M. Caligiuri, C. Bloomfield, J. Byrd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).

C. Bloomfield, M. Radmacher, R. Larson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Acceptance of Hepatitis B Vaccination Among Adult Patients With Sexually Transmitted Diseases

G. Zimet, S. Perkins, K. Maharry, 2001, Sexually transmitted diseases.